Randomized phase III study of granulocyte transfusions in neutropenic patients

Seidel, Markus G.; Peters, Christina; Wacker, A.; Northoff, Hinnak; Moog, Rainer; Boehme, Angelika; Silling, Gerda; Grimminger, W; Einsele, Hermann

doi:10.1038/bmt.2008.237

Cited by 133 publications

(112 citation statements)

References 24 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…One study was randomized, but only 60% of patients were actually neutropenic prior to receiving granulocytes, and 44% of patients randomized to the granulocyte arm received only one or two transfusions before neutrophil recovery. 23 Our study is unique in that all patients had SAA, a condition in which the response to immunosuppressive therapy can take up to 6 months to develop, leading to a neutropenic period that is typically longer than that seen after leukemia induction chemotherapy and HSCT. Fever in these severely neutropenic patients is aggressively managed with early use of broad-spectrum antibiotics and antifungal therapy.…”

Section: Discussionmentioning

confidence: 98%

“…17 Recent studies of therapeutic granulocyte transfusions for neutropenic infections in patients with leukemia and/or undergoing HSCT have shown survival rates of 31-81%; in patients with invasive fungal infections, the survival rates range from 20-80%. These studies, summarized in Table 4, [1][2][3][4][5][6][18][19][20][21][22][23][24][25] vary in the definition of invasive fungal infections, the timing of initiating granulocyte therapy, the cell dose of granulocytes transfused, and the number of granulocyte doses given. One study was randomized, but only 60% of patients were actually neutropenic prior to receiving granulocytes, and 44% of patients randomized to the granulocyte arm received only one or two transfusions before neutrophil recovery.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Quillen¹,

Wong

Scheinberg

et al. 2009

Haematologica

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Quillen¹,

Wong

Scheinberg

et al. 2009

Haematologica

View full text Add to dashboard Cite

“…A randomized study with granulocyte transfusion thrice a week in patients with neutropenic fever and pulmonary infiltrates or a history of proven invasive fungal infection (most included episodes were definite or probable invasive fungal infections) failed to confirm the benefit of this procedure [101]. By now, the real benefit of granulocyte transfusion in invasive mycoses is not doubtlessly clarified [85], but this option may be considered in very severe refractory infection courses (BIII).…”

Section: Immunotherapy and Granulocyte Transfusionmentioning

confidence: 99%

Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Böhme¹,

et al. 2008

View full text Add to dashboard Cite

International audienceInvasive fungal infections are a main cause of morbidity and mortality in cancer patients undergoing intensive chemotherapy regimens. Early antifungal treatment is mandatory to improve survival. Today, a number of effective and better-tolerated but more expensive antifungal agents compared to the former gold standard amphotericin B deoxycholate are available. Clinical decision-making must consider results from numerous studies and published guidelines, as well as licensing status and cost pressure. New developments in antifungal prophylaxis improving survival rates result in a continuous need for actualization. The treatment options for invasive infections include fluconazole, voriconazole, and amphotericin B and its lipid formulations, as well as echinocandins. Voriconazole, amphotericin B, amphotericin B lipid formulations, caspofungin, itraconazole, and posaconazole are available for the treatment of invasive aspergillosis. Additional procedures, such as surgical interventions, immunoregulatory therapy, and granulocyte transfusions, have to be considered. The Infectious Diseases Working Party of the German Society of Hematology and Oncology here presents its 2008 recommendations discussing the dos and do-nots, as well as the problems and possible solutions, of evidence criteria selection

show abstract

“…Several leading clinical trials have been conducted in Europe for platelets, red cells, and granulocyte and fresh frozen plasma transfusions, [289][290][291][292] but given the broad ranges of clinical setting where transfusions occur, many research gaps remain.…”

Section: European Research Contributionsmentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

T he European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

show abstract

Randomized phase III study of granulocyte transfusions in neutropenic patients

Cited by 133 publications

References 24 publications

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Granulocyte transfusions in severe aplastic anemia: an eleven-year experience

Treatment of invasive fungal infections in cancer patients—Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

The European Hematology Association Roadmap for European Hematology Research: a consensus document

Contact Info

Product

Resources

About